Long-term use of spironolactone for acne in women: A case series of 403 patients
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND There is limited data regarding the long-term outcomes of spironolactone use for women with acne and its effect on truncal acne. OBJECTIVE To comprehensively describe outcomes of patients treated with spironolactone in routine clinical practice, including long-term outcomes. METHODS We performed a retrospective case series of 403 adult women treated for acne with spironolactone at an academic medical center between 2008 and 2019. Rates of objective, as assessed by Comprehensive Acne Severity Scale (CASS) scores, and subjective acne clearance were evaluated, as well as rates of treatment discontinuation, dosage changes, and drug survival. Logistic regression was used to assess for association between incidence of menstrual side effects and combined oral contraceptive use. RESULTS As evaluated by CASS scores, at the first follow up, 75.5%, 84.0%, and 80.2% of patients with available data had reduction or complete clearance of acne on the face, chest, and back, respectively. The mean drug survival was 470.7 days. Menstrual side effects were less common among those using combined oral contraception (OR 0.23; 95% CI 0.11-0.50). LIMITATIONS This study was conducted at a single academic medical center. CONCLUSION Spironolactone improves clinical outcomes and is and well tolerated for many adult women with acne using it for an extended duration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · Epidemiology · doi:10.1097/ede.0b013e3181577654 · Cited by 1,991
Trends in oral antibiotic prescription in dermatology, 2008 to 2016
Barbieri, J. S., Bhate, K., Hartnett, K. P., Fleming-Dutra, K. E., & Margolis, D. J. (2019) · JAMA Dermatology · doi:10.1001/jamadermatol.2018.4944 · Cited by 97
Self-citationLong-term safety of spironolactone in acne: results of an 8-year followup study
Shaw, J. C., & White, L. E. (2002) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/120347540200600604 · Cited by 86
Cited by
Guidelines of care for the management of acne vulgaris
Reynolds, R. V., Yeung, H., Cheng, C. E., Cook-Bolden, F., Desai, S. R., Druby, K. M., Freeman, E. E., Keri, J. E., Stein Gold, L. F., Tan, J. K. L., et al. (2024) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2023.12.017 · Cited by 518
Self-citationManagement of Acne Vulgaris: A Review
Eichenfield, D. Z., Sprague, J., & Eichenfield, L. F. (2021) · JAMA · doi:10.1001/jama.2021.17633 · Cited by 389
Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis
Bommareddy, K., Hamade, H., Lopez-Olivo, M. A., Wehner, M., Tosh, T., & Barbieri, J. S. (2022) · JAMA Dermatology · doi:10.1001/jamadermatol.2021.5866 · Cited by 49
Self-citationTreatment of acne vulgaris during pregnancy and lactation: a Narrative review
Ly, S., Kamal, K., Manjaly, P., Barbieri, J. S., & Mostaghimi, A. (2023) · Dermatology and Therapy · doi:10.1007/s13555-022-00854-3 · Cited by 40
“Spironolactone Spironolactone can be effective for acne because of its antiandrogen properties [60, 93].”
BackgroundSelf-citation
Metadata
- Authors
- Garg, V., Choi, J. K., James, W. D., & Barbieri, J. S.
- Venue
- Journal of the American Academy of Dermatology
- Publisher
- Elsevier BV
- Published
- 2021-05
- Volume
- 84
- Issue
- 5
- Pages
- 1348-1355
- ISSN
- 0190-9622 (ISSN-L)
- OpenAlex
- W3118439176
- Cited by
- 37
- References
- 3
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.